共载阿霉素和维拉帕米双修饰脂质体的制备及其对MCF-7/ADR细胞增殖的抑制作用
Preparation of Doxorubicin and Verapamil loaded co-modified liposome and its growth inhibitory effects on MCF-7/ADR cells
作者：母发旭;唐洁;何勤;
Author：
收稿日期： 年卷（期）页码：2015,30(04):-396-399
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：共修饰;脂质体;阿霉素;维拉帕米;多药耐药;增殖抑制;人乳腺癌细胞MCF-7/ADR
Key words：
基金项目：国家自然科学基金资助项目(批准号:81373337);;
国家重点基础研究发展计划项目(973计划)(2013CB932504)
中文摘要
目的制备共载阿霉素(DOX)和维拉帕米(VER)双修饰脂质体[CL-R8-LP(DOX+VER)],考察其对耐药人乳腺癌细胞MCF-7/ADR增殖的抑制作用。方法采用硫酸铵梯度法制备CL-R8-LP(DOX+VER),HPLC法测定其包封率,MTT法测定不同处方制备的脂质体对MCF-7/ADR细胞增殖的抑制作用。结果所制备的CL-R8-LP(DOX+VER)粒径约90 nm,电位接近电中性;DOX和VER的包封率分别为94.96%±1.32%、70.48%±1.45%;与游离DOX和单载DOX的双修饰脂质体[CL-R8-LP(DOX)]相比,CL-R8-LP(DOX+VER)对MCF-7/ADR细胞的增殖有更强的抑制作用。结论CL-R8-LP(DOX+VER)具有治疗耐药人乳腺癌的前景。
参考文献
[1]Bergh J,Jonsson PE,Glimelius B,et al.A systematic overview of chemotherapy effects in breast cancer[J].Acta Oncol,2001,40:253-281.
[2]黄思超,徐俊,蔡绍晖.靶向逆转P-糖蛋白介导肿瘤多药耐药的研究进展[J].华西药学杂志,2009,24(5):551-554.
[3]Dean M,Allikmets R.Complete characterization of the human ABC gene family[J].J Bioenerg Biomembr,2001,33:475-479.
[4]Thiebaut F,Tsuruo T,Hamada H,et al.Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues[J].Proc Natl Acad Sci USA,1987,84:7735-7738.
[5]Borowski E,Bontemps-Gracz MM,Piwkowska A.Strategies for overcoming ABC-transporters-mediated multidrug resistance(MDR)of tumor cells[J].Acta Biochim Pol,2005,52:609-627.
[6]Tang J,Fu H,Kuang Q,et al.Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery[J].J Drug Target,2014,doi:10.3109/1061186X.2013.875029.
[7]Dong X,Mumper RJ.Nanomedicinal strategies to treat multidrug-resistant tumors:Current progress[J].Nanomedicine(Lond),2010,5(4):597-615.
[8]鄢希,侯梅,李胜富,等.维拉帕米与加温对MCF-7/Adm细胞株多药耐药的实验研究[J].华西药学杂志,2006,21(2):124-126.
[9]Shafiu AK,Maznah I,Samer HH,et al.In vitro Delivery and controlled release of Doxorubicin for targeting osteosarcoma bone cancer[J].Molecules,2013,18:10580-10598.
【关闭】
